The headline trial results will be closely monitored by pharmaceutical industry experts. Shares in Novo Nordisk, which ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

Kennedy Jr., who has been tapped by Trump to lead the HHS, has been critical of Ozempic and other weight loss drugs.

Novo Nordisk has long supplied human insulin pens to the national health department. But last year it decided not to bid for ...

Robert F. Kennedy Jr. has pledged to tackle high rates of chronic diseases such as diabetes and obesity as President-elect ...

A Scandinavian economic behemoth, Novo Nordisk is the highest valued company in Europe at over $500 billion, which exceeds Denmark’s entire GDP. Ironically, Ozempic and Wegovy, as with many of ...

"I'm using [Ozempic] off-label for a whole host of conditions — and have been for years," Dr. Caroline Messer, an ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...